China’s CNBG vaccine candidate shows promise in tests


One of the main Chinese vaccine prototypes for the new coronavirus was considered safe and elicited immune responses in initial and intermediate tests with humans, researchers announced.

The potential vaccine, called BBIBP-CorV, is being developed by the Beijing Institute of Biological Products, a subsidiary of China’s National Biotechnology Group (CNBG).

The candidate has already been approved for an emergency inoculation program in China, aimed at essential workers and other limited groups of people who face high risk of infection.

However, it will only be clear whether the vaccine can safely protect people from covid-19, which has already killed more than 1 million people worldwide, at the end of Phase 3 testing – which is currently underway outside China.

BBIBP-CorV is one of at least ten vaccine candidates developed worldwide to enter Phase 3 testing. Four of the projects are led by Chinese scientists, according to the World Health Organization (WHO).

The immunizer did not cause any serious side effects, although mild or moderate reactions, which may include fever and pain at the injection site, are common, according to a study published this Thursday in the scientific publication The Lancet.


Please enter your comment!
Please enter your name here